Valuation: CSL Limited

Market Cap 67.63B 60.57B 55.72B 50.48B 94.37B 6,422B 96.13B 664B 267B 3,378B 254B 248B 10,653B P/E 2027 *
23.3x
P/E 2028 * 21x
Enterprise Value 76.85B 68.83B 63.31B 57.36B 107B 7,297B 109B 755B 303B 3,838B 288B 282B 12,105B EV / Sales 2027 *
4.88x
EV / Sales 2028 * 4.69x
Free-Float
99.97%
Yield 2027 *
2.12%
Yield 2028 * 2.25%
1 day+0.83%
1 week+1.99%
Current month+10.49%
1 month+10.49%
3 months+55.39%
6 months+56.64%
Current year+22.53%
1 week 34.07
Extreme 34.07
35.6
1 month 30.39
Extreme 30.39
35.64
Current year 16.01
Extreme 16.01
35.64
1 year 16.01
Extreme 16.01
35.64
3 years 16.01
Extreme 16.01
54.5
5 years 16.01
Extreme 16.01
58.62
10 years 16.01
Extreme 16.01
58.99
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2026
Director of Finance/CFO 52 06/10/2025
Chief Operating Officer - 30/04/2025
Director TitleAgeSince
Director/Board Member 72 16/10/2018
Director/Board Member 70 01/02/2011
Director/Board Member 71 08/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%+1.99% - - 66.57B
+2.04%+11.31%+67.85%+150.56% 1,224B
-0.63%+3.80%+44.85%+86.24% 662B
+0.91%+3.27%+29.26%+107.89% 514B
+0.42%+3.20%+54.15%+67.18% 388B
+1.82%+3.15%+73.68%+45.94% 361B
+1.12%+4.52%+35.30%+58.08% 302B
+6.96%+8.86%+11.27%+36.62% 271B
+0.81%+6.24%+59.82%+77.32% 249B
+3.10%+9.94%+44.84%+120.59% 205B
Average +1.92%+2.59%+46.78%+83.38% 464.09B
Weighted average by Cap. +1.83%+3.04%+51.05%+98.39%

Financials

2027 *2028 *
Net sales 15.75B 14.11B 12.98B 11.76B 21.98B 1,496B 22.39B 155B 62.13B 787B 59.13B 57.87B 2,482B 16.31B 14.61B 13.44B 12.17B 22.76B 1,549B 23.18B 160B 64.32B 815B 61.21B 59.91B 2,569B
Net income 2.82B 2.52B 2.32B 2.1B 3.93B 268B 4B 27.68B 11.11B 141B 10.57B 10.35B 444B 3.14B 2.82B 2.59B 2.35B 4.39B 299B 4.47B 30.89B 12.4B 157B 11.8B 11.55B 495B
Net Debt 9.22B 8.25B 7.59B 6.88B 12.86B 875B 13.1B 90.55B 36.35B 460B 34.59B 33.85B 1,452B 8.82B 7.9B 7.27B 6.58B 12.31B 838B 12.54B 86.66B 34.79B 441B 33.1B 32.4B 1,389B
Projected Income Statement - Annual - CSL Limited
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
30/10/26 US$35.29 +0.83% 25,612
29/10/26 US$35.00 +0.69% 43,225
28/10/26 US$34.76 +0.35% 43,163
27/10/26 US$34.64 +1.41% 39,949
26/10/26 US$34.16 -1.27% 63,281
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - CSL Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
141.22USD
Average target price
133.06USD
Spread / Average Target
-5.78%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CSL Limited